Skip to content
DataLookout
Menu

NCT07777263

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 31 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Oct 2026 to Dec 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 66 words
    • Primary completion pushed from Oct 2035 to Dec 2035
    • Study completion pushed from Oct 2040 to Dec 2040
    • Secondary endpoints: details revised at 4 of 10 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

5-year biochemical failure-free survival (bFFS)
Timeframe: 5 years

Secondary (10)

Metastasis-free survival
Overall survival
Prostate cancer-specific mortality
8-year biochemical failure-free survival (bFFS)
Toxicity - Acute
Show 5 moreShow less
Toxicity - Late
Quality of Life - General
Quality of Life - Pain
Quality of Life - Fatigue
Testosterone Recuperation

Arms and interventions

Arm 1 (experimental): 12 months of ADT + RadiotherapyExperimental

Zoladex is given for 12 months instead of 24

Arm 2 (standard of care): 24 months of ADT + RadiotherapyActive comparator

Drugs: ZOLADEX 10.8 mg

Sites

1 site in 1 country

  • Jewish General HospitalMontreal, Quebec, Canada